Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focusing on mRNA cell therapies for autoimmune diseases, has granted an inducement award to a new employee. The award, issued on September 3, 2024, consists of an option to purchase 3,864 shares of the company's common stock at an exercise price of $13.12 per share. This price reflects the closing price of RNAC on Nasdaq on the grant date.
The option, approved by the board of directors, falls under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan. It has a four-year vesting schedule, with 25% vesting on September 3, 2025, and the remainder vesting in three equal annual installments until fully vested by September 3, 2028. The option has a ten-year term and was granted under Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Cartesian Therapeutics (NASDAQ: RNAC), una società biotecnologica in fase clinica che si concentra sulle terapie cellulari mRNA per le malattie autoimmuni, ha concesso un premio di indennizzo a un nuovo dipendente. Il premio, emesso il 3 settembre 2024, consiste in un opzione per acquistare 3.864 azioni delle azioni ordinarie della società a un prezzo di esercizio di $13,12 per azione. Questo prezzo riflette il prezzo di chiusura di RNAC su Nasdaq nella data di concessione.
L'opzione, approvata dal consiglio di amministrazione, rientra nel Piano di Incentivazione all'Impiego 2018 Ampliato e Modificato della società. Ha un programma di vesting di quattro anni, con il 25% che matura il 3 settembre 2025 e il resto che matura in tre rate annuali uguali fino a essere completamente maturato entro il 3 settembre 2028. L'opzione ha un termine di dieci anni ed è stata concessa ai sensi della Regola di Quotazione Nasdaq 5635(c)(4) come indennizzo all'impiego.
Cartesian Therapeutics (NASDAQ: RNAC), una empresa biotecnológica en etapa clínica que se centra en terapias celulares de ARNm para enfermedades autoinmunes, ha otorgado un premio de inducción a un nuevo empleado. El premio, emitido el 3 de septiembre de 2024, consiste en una opción para comprar 3,864 acciones de las acciones comunes de la empresa a un precio de ejercicio de $13.12 por acción. Este precio refleja el precio de cierre de RNAC en Nasdaq en la fecha de concesión.
La opción, aprobada por la junta directiva, se enmarca en el Plan de Incentivos de Inducción de Empleo 2018 Modificado y Restablecido de la empresa. Tiene un programa de consolidación de cuatro años, con el 25% consolidándose el 3 de septiembre de 2025, y el resto consolidándose en tres cuotas anuales iguales hasta que esté completamente consolidado para el 3 de septiembre de 2028. La opción tiene un plazo de diez años y fue otorgada bajo la Regla de Inclusión de Nasdaq 5635(c)(4) como un incentivo de empleo.
카르테시안 치료제(Cartesian Therapeutics) (NASDAQ: RNAC), 자가 면역 질환을 위한 mRNA 세포 치료제에 집중하는 임상 단계의 생명공학 회사가 새로운 직원에게 유인 보상을 수여했습니다. 이 보상은 2024년 9월 3일에 발급되었으며 회사의 보통주 3,864주를 구매할 수 있는 선택권으로 구성되어 있으며, 행사 가격은 주당 $13.12입니다. 이 가격은 보상 발급일의 RNAC의 나스닥 종가를 반영합니다.
이 선택권은 이사회에 의해 승인되었으며 회사의 수정 및 재설정된 2018 고용 유인 보상 계획에 따라 진행됩니다. 이 보상은 4년의 베스팅 일정을 가지고 있으며, 25%는 2025년 9월 3일에 베스트되고, 나머지는 2028년 9월 3일까지 전체가 베스팅될 때까지 3개의 동일한 연간 할부로 베스트 됩니다. 이 선택권은 10년의 기간을 가지며, 고용 유인으로서 나스닥 상장 규정 5635(c)(4)에 따라 부여되었습니다.
Cartesian Therapeutics (NASDAQ: RNAC), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies cellulaires à ARNm pour les maladies auto-immunes, a accordé une récompense d'incitation à un nouvel employé. La récompense, attribuée le 3 septembre 2024, consiste en une option d'achat de 3 864 actions de l'entreprise à un prix d'exercice de 13,12 $ par action. Ce prix reflète le prix de clôture de RNAC sur le Nasdaq à la date d'attribution.
L'option, approuvée par le conseil d'administration, relève du Plan 2018 modifié et restitué d'incitation à l'emploi de l'entreprise. Elle a un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition le 3 septembre 2025, et le reste qui s'acquiert en trois versements annuels égaux jusqu'à être entièrement acquis le 3 septembre 2028. L'option a un terme de dix ans et a été accordée en vertu de la Règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation à l'emploi.
Cartesian Therapeutics (NASDAQ: RNAC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf mRNA-Zelltherapien für Autoimmunerkrankungen spezialisiert, hat einem neuen Mitarbeiter eine Anreizvergütung gewährt. Die Vergütung, die am 3. September 2024 ausgestellt wurde, besteht aus einer Option zum Kauf von 3.864 Aktien des Unternehmens zu einem Ausübungspreis von 13,12 $ pro Aktie. Dieser Preis entspricht dem Schlusskurs von RNAC an der Nasdaq am Gewährungstag.
Die Option, die vom Vorstand genehmigt wurde, fällt unter den geänderten und neu gefassten 2018 Employment Incentive Award Plan des Unternehmens. Sie hat einen vierjährigen Vesting-Plan, bei dem 25 % am 3. September 2025 und der Rest in drei gleichmäßigen Jahresraten bis zum vollständigen Vesting am 3. September 2028 fällig wird. Die Option hat eine Laufzeit von zehn Jahren und wurde gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für die Beschäftigung gewährt.
- Cartesian Therapeutics is attracting new talent with stock options as incentives
- The company has a structured vesting schedule for employee stock options, potentially aiding in retention
- None.
GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On September 3, 2024, the Company issued to this employee an option to purchase 3,864 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Melissa Forst
Argot Partners
cartesian@argotpartners.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
What type of inducement award did Cartesian Therapeutics (RNAC) grant to a new employee?
When will the stock option granted by Cartesian Therapeutics (RNAC) fully vest?
What is the exercise price of the stock option granted by Cartesian Therapeutics (RNAC) on September 3, 2024?
Under which plan was the inducement award granted by Cartesian Therapeutics (RNAC)?
